Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement
Gianluigi Reda(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Massimo Zucchetti(Mario Negri Institute for Pharmacological Research), Gabriela Dovrtělová(Mario Negri Institute for Pharmacological Research), Maurizio D’Incalci(Humanitas University), Juri Alessandro Giannotta(University of Milan), Cristina Matteo(Mario Negri Institute for Pharmacological Research), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Ramona Cassin(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 67
Related Papers
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Angiogenesis in myelodysplastic syndromes
|British Journal of Cancer|1999|272
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
|Leukemia|2018|250